BiotechTube
53Biologics

53Biologics

Barcelona, Spain· Est.
53biologics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Founded in 2019 and based in Barcelona, Spain, 53Biologics is a rapidly growing, privately-held CDMO focused on the biologics sector. The company provides comprehensive development and manufacturing services for plasmid DNA and recombinant proteins, catering primarily to international biotech and pharmaceutical clients. With over 4,500 sqm of facilities, including cGMP manufacturing suites and a strong portfolio of quality certifications (ISO, GMP), 53Biologics is positioned as a flexible and scalable partner for advanced therapy and biologics production. Its recognition, such as winning the 2025 SME of the Year Award, underscores its operational excellence and growth trajectory.

BiologicsAntibodies

Technology Platform

Integrated biologics CDMO platform for plasmid DNA and recombinant protein production. Services span strain/cell line development, banking, process development (USP/DSP), analytical development, cGMP/non-GMP manufacturing, and fill-finish. Utilizes both microbial (E. coli) and mammalian expression systems with flexible equipment (single-use, stainless steel).

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The booming market for advanced therapies (gene, cell, mRNA) drives unprecedented demand for high-quality plasmid DNA manufacturing, a core specialty.
Expansion into larger-scale cGMP production with a new 2,000L reactor allows the company to capture more valuable late-stage clinical and commercial contracts.
Its strong reputation and international client base (90% outside Spain) provide a platform for sustained growth and potential strategic partnerships.

Risk Factors

Revenue is tied to the health of the biotech funding ecosystem, which is cyclical and can lead to client project delays or cancellations.
The company faces intense competition from large global CDMOs and niche players, requiring constant investment and flawless execution.
Operational risks include technical failures during scale-up or regulatory compliance issues in cGMP manufacturing, which could damage its reputation.

Competitive Landscape

53Biologics competes in the crowded global biologics CDMO market against giants like Lonza, Catalent, and Samsung Biologics, as well as specialized European peers. Its differentiation lies in a focused end-to-end offering for pDNA and proteins, operational flexibility, high-quality certifications, and a strategic location in Spain serving international clients. The recent capacity expansion allows it to compete for larger-scale projects.

More companies in Biologics / Biosimilars →More companies in Spain →